The GLP-1 shortage that ran from 2022 through early 2025 was formally resolved in February 2025, but supply remains structurally tight and demand continues to grow as more patients start treatment
For Mounjaro-related adverse effects, the appropriate external cause code is Y42.3 (Insulin and oral hypoglycaemic [antidiabetic] drugs causing adverse effects in therapeutic use)
These can include: Nausea or vomiting Constipation or diarrhea Fatigue or reduced appetite Rapid fat loss may cause hanging skin on the face and body (e.g., Ozempic face) To minimize discomfort, providers usually start at a low dose and slowly increase it
The relevant question isnt why does this cost more than the nurse clinic but whats the value of having a plastic surgeon do this rather than a nurse
Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells
Decision-Making in Drug Selection : Choosing appropriate therapy based on patient-specific factors such as age, symptom severity, and side effect profiles